rawfin.tv
Eli Lilly Loses India GLP-1 Market Share to Generics; Novo Nordisk Holds Steady
MarketsstocksAI Generated

Eli Lilly Loses India GLP-1 Market Share to Generics; Novo Nordisk Holds Steady

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Eli Lilly's market share in India's GLP-1 drug sector is declining due to a surge in cheap generic alternatives. Meanwhile, competitor Novo Nordisk has managed to maintain its position despite the increased competition.

Eli LillyNovo NordiskPharmaceuticalsGenericsIndia MarketGLP-1

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks